| Species |
Human |
| Protein Construction |
HGFR/c-MET (Glu25-Thr932)
Accession # P08581 |
Poly-His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
≤ 1 EU/μg of protein by LAL method |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized HGFR/c-MET, His & Avi, Human at 2 μg/ml (100 μl/Well). Dose response curve for Human HGF, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
The mature form of HGF R is a heterodimer which can be cleaved into α and β chain. The protein has a predicted MW of 32.5 kDa (α chain) and 72.1 kDa (β chain). |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 45-60 kDa (α subunit) and 80-100 kDa (β subunit) based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH?O more than 100 μg/ml. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized Human c-MET, His & Avi Tag at 2 μg/ml (100 μl/Well). Dose response curve for Human HGF, hFc Tag with the EC50 of 0.16 μg/ml determined by ELISA.
Human HGFR/c-MET on SDS-PAGE under reducing conditions. The purity is greater than 95%.
The purity of Human HGFR/c-MET is greater than 95% as determined by SEC-HPLC.
| Target Background |
c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling. |
| Synonyms |
MET; oncogene MET; Proto-oncogene c-Met; HGF R; HGF receptor; HGF/SF receptor; HGFR; AUTS9; cMET; c-MET; EC 2.7.10; EC 2.7.10.1; hepatocyte growth factor receptor;?Met (c-Met); met proto-oncogene (hepatocyte growth factor receptor); met proto-oncogene tyrosine kinase; RCCP2; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
